Aradigm Corp is a United States-based company. The Company is an emerging specialty pharmaceutical company focused on the development and commercialization of drugs for the prevention and treatment of severe respiratory diseases. Its inhaled ciprofloxacin formulations are also product candidates for treatment of patients with cystic fibrosis and non-tuberculous mycobacteria, and for the prevention and treatment of high threat and bioterrorism infections, such as inhaled tularemia, pneumonic plague, melioidosis, Q fever and inhaled anthrax.

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Cap	4.89M 4.23M 3.96M 3.62M 6.81M 466M 6.92M 46.47M 18.21M 233M 18.34M 17.94M 778M	P/E 2016	-0.72x	P/E 2017	-9.3x
Enterprise Value	12.8M 11.09M 10.38M 9.47M 17.83M 1.22B 18.13M 122M 47.7M 611M 48.05M 47.01M 2.04B	EV / Sales 2016	73.3x	EV / Sales 2017	7.27x
Free-Float	60.28%	Yield 2016 *	-	Yield 2017	-

29/06/20	Aradigm Corporation Went Out of Business	CI
12/06/20	Modified Combined Liquidation Plan and Discosure Statement Approved for Aradigm Corporation	CI
27/04/20	Revised Disclosure Statement Conditionally Approved for Aradigm Corporation	CI
08/04/20	Combined Liquidation Plan and Disclosure Statement Filed by Aradigm Corporation	CI
31/03/20	Grifols, S.A. completed the acquisition of Assets and Intellectual Property of Lipoquin, Free Ciprofloxacin, Apulmiq from Aradigm Corporation (OTCPK:ARDM.Q).	CI
30/03/20	Motion for Asset Sale Approved for Aradigm Corporation	CI
09/03/20	Bidding Procedure Approved for Aradigm Corporation	CI
21/02/20	Motion for Asset Sale Filed by Aradigm Corporation	CI
21/02/20	Grifols, S.A. entered into an asset purchase agreement to acquire Assets and Intellectual Property of Lipoquin, Free Ciprofloxacin, Apulmiq from Aradigm Corporation (OTCPK:ARDM.Q) for $6.3 million.	CI
06/11/19	Second Motion for Exclusivity Period Extension Approved For Aradigm Corporation	CI
31/10/19	Aradigm Corporation Announces Withdrawal of European Marketing Authorization Application for Linhaliq	CI
22/10/19	Aradigm Corporation Receives Feedback Following an Oral Explanation with the European Medicines Agency	CI
19/07/19	Motion for Exclusivity Period Extension Approved For Aradigm Corporation	CI

16/06/20	ARADIGM CORP : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
04/06/20	ARADIGM CORP : Other Events (form 8-K)	AQ
30/04/20	ARADIGM CORP : Other Events, Financial Statements and Exhibits (form 8-K)	AQ
13/04/20	ARADIGM CORP : Other Events (form 8-K)	AQ
06/04/20	Aradigm : Announces Sale of Assets to Grifols, S.A.	AQ

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ARADIGM CORPORATION	+36.88%	+25.50%	-	-	702K
LONZA GROUP AG	-0.72%	+3.41%	+6.32%	+16.27%	50.03B
REVOLUTION MEDICINES, INC.	-0.86%	+5.38%	+487.51%	+579.78%	44.36B
BEONE MEDICINES AG	+0.73%	+11.95%	+24.80%	+82.93%	40.82B
IQVIA HOLDINGS INC.	+0.69%	+6.90%	+35.46%	+10.97%	39.83B
CELLTRION, INC.	+4.73%	+15.53%	+26.95%	+54.62%	32.51B
ASCENDIS PHARMA A/S	-0.40%	+3.75%	-	-	16.85B
MEDPACE HOLDINGS, INC.	+0.33%	+5.19%	+34.50%	+126.66%	16.81B
EUROFINS SCIENTIFIC SE	-0.20%	+1.57%	+5.49%	+21.35%	14.05B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+0.78%	+19.44%	+87.77%	+30.39%	13.22B
Average	+4.21%	+279.97%	+88.60%	+115.37%	29.83B
Weighted average by Cap.	+0.56%	+295.32%	+107.54%	+138.94%

	2016	2017
Net sales	195K 169K 158K 144K 272K 18.6M 276K 1.85M 727K 9.31M 732K 716K 31.06M	14.46M 12.54M 11.74M 10.71M 20.15M 1.38B 20.49M 138M 53.91M 691M 54.31M 53.13M 2.3B
Net income	-32.94M -28.54M -26.72M -24.38M -45.88M -3.14B -46.65M -313M -123M -1.57B -124M -121M -5.25B	-10.7M -9.28M -8.68M -7.92M -14.91M -1.02B -15.16M -102M -39.9M -511M -40.19M -39.32M -1.7B
Net Debt	-9.37M -8.12M -7.6M -6.94M -13.06M -894M -13.27M -89.15M -34.93M -447M -35.19M -34.42M -1.49B	7.91M 6.86M 6.42M 5.86M 11.02M 755M 11.21M 75.27M 29.49M 378M 29.71M 29.06M 1.26B

Aradigm Corporation Stock Nasdaq

Stocks

US0385054004

Biotechnology & Medical Research

Valuation: Aradigm Corporation

Latest news : Aradigm Corporation

Press Releases: Aradigm Corporation

Quotes and Performance

Other Biotechnology & Medical Research

Financials

Company Profile